Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,117 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease Clear all
Completed No phase listed Observational

New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

NCT04426539
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 1 Interventional

A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.

NCT07218081
View directory record Official record
Conditions
Alzheimer Dementia (AD)
Interventions
Intermittent deep brain stimulation of the nucleus basalis of Meynert
Device
Lead sponsor
Augusta University
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Not listed No phase listed Observational

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

NCT06025877
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Interventions
PrecivityAD2(TM) blood test
Other
Lead sponsor
C2N Diagnostics
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Timeline
2023 – 2025
U.S. locations
9
States / cities
San Francisco, California • Santa Monica, California • Park Ridge, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 22, 2026, 6:45 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Learning Amyloid and Tau Results

NCT07222930
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Disclose amyloid, tau results, Follow-up Assessments
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
45 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Assess Fibrin in Brains With AD/ADRD

NCT05336695
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
PET/MR Imaging, 64Cu-FBP8
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 22, 2026, 6:45 AM EDT
Withdrawn Not applicable Interventional

Virtual Communication in the Hospital: Impact on Patients and Surrogates

NCT05395039
View directory record Official record
Conditions
Communication, Anxiety, Depression, Distress, Emotional
Interventions
VCHIPS
Other
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed No phase listed Observational

Florbetaben PET Imaging in PPA

NCT04720001
View directory record Official record
Conditions
Primary Progressive Aphasia, Alzheimer Disease
Interventions
Florbetaben F18, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01690195
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Long Beach, California • San Francisco, California • Hamden, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rhythmically Entrained Exercise in Community-Dwelling Older Adults

NCT05462977
View directory record Official record
Conditions
Exercise, Gait, Cognitive Decline, Caregiver Burden, Cognitive Impairment, Dementia, Alzheimer Disease, Mild Cognitive Impairment, Respite Care, Mental Health, Depression, Music Therapy, Psychosocial Intervention, Cognition, Geriatric Assessment, Cognitive Dysfunction, Cognitive Aging, Outcome Assessment, Health Care, Balance, Fall, Walking, Affect, Physical Exertion, Memory Deficit, Memory Disorders, Memory Impairment, Neuropsychological Tests, Executive Function, Middle Aged, Healthy Aging, Elderly
Interventions
Group exercise program
Behavioral
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
55 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults

NCT04480112
View directory record Official record
Conditions
Memory Disorders, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Technology based social interactions, No research related technology based social interactions
Behavioral · Other
Lead sponsor
Boston University
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

NCT04268953
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tricaprilin
Drug
Lead sponsor
Cerecin
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

CB3 Pilot (Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia)

NCT05697380
View directory record Official record
Conditions
Aphasia, Primary Progressive Aphasia, Dementia, Communication, Alzheimer Disease
Interventions
Communication Bridge™
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Results available

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

NCT02036645
View directory record Official record
Conditions
Mild-Moderate Alzheimer's Disease, Healthy Elderly
Interventions
MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Glendale, California • Long Beach, California • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT04947553
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Peoria, Arizona • Tempe, Arizona • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Neuroinflammation and Alzheimer's Pathology in POCD

NCT05378659
View directory record Official record
Conditions
Post-Operative Confusion, Neuroinflammatory Response, Alzheimer Disease
Interventions
Montreal Cognitive Assessment, Stroop Test, 4AT Delirium, Grooved Pegboard, NACC Cognitive Battery, ERP Testing, Blood Plasma and Serum sampling, Cerebral Spinal Fluid Sample
Behavioral · Diagnostic Test
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Translating a Dementia Caregiver Intervention Into a Mobile Application

NCT04330482
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Caregiver Burnout
Interventions
CARE-Well App, Internet Links
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Kingston, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional

Remote tDCS and Chair Yoga for Chronic Knee Pain in Alzheimer's Patients

NCT07303998
View directory record Official record
Conditions
Alzheimer&Amp;#39;s Disease, Other Dementias
Interventions
Active tDCS paired with active online chair yoga
Device
Lead sponsor
University of Arizona
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 22, 2026, 6:45 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Tdap and Biomarkers of Alzheimer's Disease

NCT05183516
View directory record Official record
Conditions
Alzheimer Disease, Late Onset
Interventions
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Biological
Lead sponsor
Mindful Diagnostics and Therapeutics, LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Enrolling by invitation No phase listed Observational

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)

NCT02414178
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Not yet recruiting Phase 2 Interventional

Flutemetamol F 18 Injection Formulation Comparison

NCT07873463
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
GE-287, Vizamyl
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
50 Years to 110 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Aventura, Florida • Merritt Island, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults With ADRD

NCT04780178
View directory record Official record
Conditions
Anxiety, Caregiver Burden
Interventions
Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

NCT02442778
View directory record Official record
Conditions
Agitation in Participants With Dementia of the Alzheimer's Type
Interventions
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 22, 2026, 6:45 AM EDT